Leaders in pulmonary hypertension

Neil Davie, Ph.D. is the Head, Late Development, of Cardiovascular, Metabolism, & Pulmonary Hypertension (CVM & PH). He has extensive experience as a drug developer leading projects across multiple therapeutic areas, particularly in specialty/rare diseases with high unmet medical need.

Emmanuelle Quilès is Worldwide Vice President, Cardiovascular, Metabolism and Pulmonary Hypertension. In this role, working closely with R&D, Emmanuelle is focusing on maximizing the value of Janssen’s Cardiovascular & Metabolism (CVM) and Pulmonary Hypertension (PH) pipelines and marketed assets.